Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Future Oncology (London, England)|September 4, 2023
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanomaAlexander Cj van Akkooi, Axel Hauschild, Georgina V Long, et al.
The Lancet. Oncology|September 8, 2012
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trialPenella J Woll, Peter Reichardt, Axel Le Cesne, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trialsCarine A Bellera, Marina Pulido, Sophie Gourgou, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
Oncotarget|May 31, 2018
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myelomaGuillemette Fouquet, Stéphanie Guidez, Valentine Richez, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
Pageof 2